Aurora Tells Shareholders to Reject Curaleaf Hostile Bid, Pointing to $1B Debt Versus Its $149M Cash

35,000+ smart investors are already getting financial news, market signals, and macro shifts in the economy that could impact their money next with our FREE weekly newsletter. Get ahead of what the crowd finds out too late. Click Here to Subscribe for FREE.

Aurora Cannabis has escalated its defence against Curaleaf Holdings, formally urging shareholders to reject an unsolicited takeover offer that has turned into one of the cannabis sector’s most closely watched corporate battles. Aurora’s board unanimously concluded the bid is not in shareholders’ best interests after reviewing it with independent directors and outside financial and legal advisers. At the centre of Aurora’s argument is a dramatic balance-sheet contrast: the Edmonton-based company says it has roughly C$149 million in cash, equivalents and short-term investments and no debt, while Curaleaf carries more than $1 billion in debt and related financial obligations. Curaleaf strongly disputes Aurora’s broader valuation case, arguing its cash-and-stock proposal offers shareholders an immediate premium, greater scale and exposure to a more diversified cannabis business.

Aurora’s Board Has Moved From Reviewing the Bid to Rejecting It

Aurora’s position is no longer simply that shareholders should wait. On September 2, the company filed its directors’ circular and said its board unanimously recommends that investors take no action and not tender their shares to Curaleaf. Aurora also advised shareholders who have already tendered to withdraw those shares. The recommendation followed a review by a special committee consisting of independent directors, with financial and legal advisers participating in the process. Aurora said its financial adviser delivered a written opinion dated September 1 that is included in the circular.

That distinction matters in a hostile takeover. Curaleaf is trying to acquire Aurora without first reaching a negotiated agreement with its board, meaning shareholders ultimately become the audience both sides must persuade. Aurora Executive Chairman and CEO Miguel Martin says Curaleaf is trying to buy a transformed global medical-cannabis company at a discount. Curaleaf CEO Boris Jordan says Aurora’s board has failed to demonstrate why shareholders should believe the standalone company will ultimately produce more value. The dispute has therefore moved beyond whether the companies fit strategically; it has become a direct argument over what Aurora is worth.

Curaleaf Is Offering Cash and Shares — But the Share Price Matters

Curaleaf formally launched its takeover bid on August 18 after announcing its intentions a week earlier. The proposal offers US$0.75 in cash plus 0.3463 Curaleaf subordinate voting shares for every Aurora common share. Based on Curaleaf’s August 10 closing price of US$9.39, Curaleaf calculated the package at approximately US$4 per Aurora share. The bidder described that as a 45% premium to Aurora’s 30-day volume-weighted average price of US$2.75 before the proposed transaction became public.

This is not a fixed US$4 cash bid, however. Most of the consideration comes in Curaleaf stock, meaning its ultimate market value can move with Curaleaf’s share price. There is also an upside cap: the consideration is limited to US$5 per Aurora share under a formula that can reduce the number of Curaleaf shares issued if Curaleaf’s stock rises sufficiently before the calculation date. Aurora has seized on that provision, arguing shareholders would accept market risk while having part of their potential upside restricted. Curaleaf counters that even the US$5 ceiling would represent a substantial premium over Aurora’s pre-bid trading level.

The $149 Million Versus $1 Billion Comparison Needs Context

Aurora’s strongest headline argument comes from the two companies’ balance sheets. At June 30, Aurora reported C$149.1 million of cash, cash equivalents and short-term investments and said it had no debt. Its September 2 materials use that financial flexibility to argue shareholders should not exchange ownership of a debt-free company for shares in a more leveraged acquirer. Aurora portrays its liquidity as capital that can fund international growth, acquisitions and operating improvements rather than effectively passing under Curaleaf’s control.

Curaleaf’s filings show why Aurora can credibly describe its obligations as exceeding $1 billion, although the comparison requires care. Curaleaf reported approximately US$611.5 million of notes payable after unamortized discounts and financing fees at June 30. It also carried hundreds of millions of dollars of finance and operating lease liabilities and approximately US$205.6 million of financial obligations tied largely to failed sale-and-leaseback arrangements. Curaleaf’s financial statements are primarily presented in U.S. dollars, while Aurora’s C$149.1 million figure is Canadian. In other words, the headline comparison is directionally meaningful, but it should not be interpreted as two identical accounting measures denominated in the same currency.

Aurora’s Recent Numbers Give Both Sides Evidence to Use

Aurora’s latest quarter helps explain why the takeover argument is unusually complicated. For the three months ended June 30, the company reported C$67.6 million in total net revenue, down approximately 9% from C$74.1 million a year earlier. Adjusted EBITDA fell to C$3.4 million from C$10.8 million. Free cash flow swung to an outflow of C$5.8 million from an inflow of C$6.8 million, while operating cash flow from continuing operations was negative C$4.4 million.

Those figures provide Curaleaf with ammunition, but the same quarter also supports Aurora’s claim that an important part of its strategy is working. International medical-cannabis revenue increased 17% to C$43.3 million, driven largely by increased German demand. Aurora also reported a C$4 million net loss from continuing operations, narrower than C$10.2 million a year earlier. Medical cannabis accounted for C$64 million of the quarter’s C$67.6 million in net revenue. The result is not a straightforward growth story: Aurora is smaller in some areas and generating less EBITDA, but its increasingly important international medical business is expanding.

International Medical Cannabis Is the Asset Aurora Wants Shareholders to Value

Aurora’s defence rests heavily on the idea that its future should be judged differently from its past. The company has been winding down its Canadian consumer-cannabis business and directing resources toward medical markets in Canada and countries including Germany, Poland, Australia and New Zealand. That strategy was visible in the June quarter, when international medical revenue grew while Canadian medical revenue fell 25% to C$20.7 million following changes to a federal reimbursement program that reduced reimbursement rates by roughly 30%.

Aurora is also investing in manufacturing capacity designed for regulated international markets. Its April acquisition of Safari Flower Company added a 59,000-square-foot indoor cultivation and manufacturing facility in Ontario. Safari subsequently received a three-year EU-GMP certification, which is important for supplying tightly regulated European medical markets. Aurora plans approximately C$3.5 million of capital improvements at the operation over three years. The board’s argument is essentially that these assets, certifications, genetics and regulatory capabilities would be difficult and expensive to recreate, and Curaleaf is attempting to secure them before their international growth potential is fully reflected in Aurora’s valuation.

Curaleaf Says Scale and Cash Generation Make the Combination Stronger

Curaleaf presents almost the opposite interpretation. Its argument is that Aurora shareholders should not focus only on how much debt Curaleaf carries, because Curaleaf operates a substantially larger business and generates meaningful operating cash. Curaleaf reported second-quarter 2026 revenue of approximately US$340 million, adjusted EBITDA of US$70 million and net income of US$12 million. In its takeover materials, the company said it generated roughly US$145 million of operating cash during the 12 months ended June 30.

Curaleaf estimates a combined company would have more than US$1.5 billion in trailing-12-month revenue and nearly US$350 million of adjusted EBITDA. It has also identified at least US$40 million of potential annual cost synergies from areas such as corporate overhead, procurement, supply-chain operations and international infrastructure. Those numbers are projections rather than guaranteed savings, but they explain Curaleaf’s strategic pitch. Aurora brings international medical-cannabis cultivation, genetics and EU-GMP capabilities; Curaleaf brings a much larger operating platform, U.S. exposure and international distribution infrastructure. For shareholders, the debate is whether those benefits adequately compensate for Curaleaf’s leverage and the price being offered.

Voting Power Has Become One of Aurora’s Biggest Governance Objections

Aurora is also warning that the transaction would change more than the ticker symbol held by its shareholders. Based on the proposed exchange ratio, Aurora estimates its shareholders would own roughly 7.7% of the combined company economically but control only approximately 3.2% of its votes. The gap comes from Curaleaf’s multiple-voting-share structure, which concentrates substantial voting power in shares held directly or indirectly by CEO and Chairman Boris Jordan.

Curaleaf’s own June 30 filing shows the extent of that structure. Its subordinate voting shares carry one vote each, while multiple voting shares carry 15 votes apiece. At the end of June, the multiple voting shares represented about 11.8% of Curaleaf’s outstanding shares but controlled approximately 66.8% of its total voting power. For an Aurora investor accustomed to holding an ordinary common share, that distinction is significant. Shareholders tendering into the offer would receive Curaleaf subordinate voting shares, giving them participation in the company’s economics without proportionate influence over corporate decisions. Aurora argues that this makes the offer less attractive than a simple headline premium might suggest.

Curaleaf Says Aurora’s Debt-Free Status Came at a Cost

Curaleaf responded to Aurora’s circular within hours on September 2, arguing that concentrating on debt ignores how Aurora financed its own balance-sheet repair. Curaleaf says Aurora has repeatedly sold equity through at-the-market programs, raising hundreds of millions of dollars since 2020 while diluting existing shareholders. It pointed specifically to Aurora issuing stock at average prices of roughly US$3.57 during fiscal 2026 and US$3.09 during the June quarter — below the US$4 implied value Curaleaf assigns to its current offer.

Curaleaf also highlighted Aurora’s negative June-quarter operating cash flow and weaker year-over-year adjusted EBITDA. Those points are grounded in Aurora’s own financial results, even though Curaleaf’s conclusions remain part of the takeover sales pitch. Aurora’s counterargument is that eliminating debt and raising capital left it with a stronger platform from which to pursue international opportunities. This makes the takeover fight less about whether either side can find an uncomfortable financial statistic and more about what those statistics mean. Curaleaf sees past dilution and cash burn; Aurora sees a repaired balance sheet and an international medical business positioned for investment.

Aurora Has Been on the Other Side of a Hostile Cannabis Takeover

There is an unusual historical twist to the battle: Aurora itself helped establish the playbook Curaleaf is now using against it. In late 2017, Aurora launched a hostile takeover effort for CanniMed Therapeutics after failing to secure a negotiated transaction. CanniMed resisted, and the fight became one of the Canadian cannabis industry’s earliest major takeover battles. The dispute ultimately ended in a negotiated agreement rather than a simple victory at the original hostile-bid price.

The final CanniMed transaction was worth approximately C$1.1 billion. Aurora raised its offer substantially, from a previous value capped at C$24 per CanniMed share to an improved transaction valued around C$43 per share, and added a cash component. By March 2018, Aurora had taken up more than 86% of CanniMed’s outstanding shares on a fully diluted basis, later acquiring the remainder. That history does not predict what will happen with Curaleaf, but it illustrates why initial hostile bids are not necessarily final outcomes. A target board can resist, shareholders can hold out and negotiations can eventually produce different economics.

Shareholders Still Have Time, and the Fight Could Change Again

Curaleaf’s offer is currently scheduled to remain open until 5 p.m. Mountain Time on December 1, 2026, unless it is extended, accelerated or withdrawn under its terms. The bid includes several conditions. Among them, more than 50% of eligible Aurora shares must be tendered and not withdrawn, and Curaleaf has also stipulated that at least 66⅔% of Aurora shares on a fully diluted basis must be deposited. Required regulatory approvals and other closing conditions must also be satisfied.

Canadian takeover rules are deliberately structured to give shareholders time in situations like this. Non-exempt bids are generally subject to a 105-day minimum deposit period, a requirement that more than 50% of independent shares be tendered before the bidder can take them up, and an additional extension once the minimum tender threshold and other conditions are satisfied. That gives Aurora time to continue making its standalone case, explore alternatives or potentially engage with Curaleaf on changed terms. Curaleaf, meanwhile, has said it remains willing to talk. The outcome therefore remains open: shareholders are being asked to choose between immediate takeover value and Aurora’s argument that patience could ultimately be worth more.

This Options Discord Chat is The Real Deal

While the internet is scoured with trading chat rooms, many of which even charge upwards of thousands of dollars to join, this smaller options trading discord chatroom is the real deal and actually providing valuable trade setups, education, and community without the noise and spam of the larger more expensive rooms. With a incredibly low-cost monthly fee, Options Trading Club (click here to see their reviews) requires an application to join ensuring that every member is dedicated and serious about taking their trading to the next level. If you are looking for a change in your trading strategies, then click here to apply for a membership.